In addition to improving the lives of these patients, T Cell therapies possess the potential to address countless other disease states. As such, the T cell therapy market has recently flourished and is expected to grow to $20.3 billion by 2028. In this rapidly expanding field, automation, improved control, and preparation for effective scale-up are critical to the success of these therapies. This has led cell therapy manufacturers to lean heavily on the use of bioreactors for cell expansion, because of their closed and automated design as well as their ability to create an optimal cell environment.
Learn about what to considering when scaling up to larger bioreactors, along with a process that was developed for expanding T cells in a 3 L HyPerforma Glass Bioreactor using CTS OpTmizer Pro SFM.